Specialty General Scientific
Oliver Bohnsack, MD PhD MBA
Vice President, Medical Imaging & Head of Oncology
In leading the imaging component of oncology studies for Calyx’s global customers, Oliver leverages his experience from supporting over 600 clinical trials – with various indications, complexities, and in all phases of development – which led to the approval of over 20 oncology treatments. He is co-author of the immune-related response criteria (irRC, 2009), first author of irRECIST (2014), and co-author of Comparison of Assessments using RECIST and irRECIST by Manitz J. et al. (2020).